Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc announced the initiation of a phase II study-EV-201 of enfortumab ...

The revenue increase leaders of the fourth quarter were familiar—Eli Lilly (45%) and Novo Nordisk ... drug conjugate drugs brought by the Seattle biotech—played a significant role in boosting ...

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

The bonus is part of a bid to induce CFO Cathy Smith to join the coffee retailer as well as to help her recoup some of the ...

Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Fig 1. Challenges in the management of advanced prostate cancer.

Loi reported relationships with Bristol Myers Squibb, Puma Biotechnology, AstraZeneca-Daiichi Sankyo, Novartis, Roche-Genentech, Seattle Genetics, MSD, Gilead Sciences, Eli Lilly, Amaroq ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population could be eligible to take them ...

Many celebrities are investing in NWSL franchises, including Kevin Durant, Serena Williams, Patrick Mahomes and more.